[en] Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. Aspirin prescription is mandatory in secondary prevention, even if the protection by aspirin appears less efficacious in diabetic than in non-diabetic patients. In primary prevention, available data are paradoxically rather scarce, but also suggest a less effective prevention when diabetes is present. Aspirin remains the first antiplatelet agent in the diabetic population in all international guidelines of cardiovascular prevention although a higher daily dose may be proposed in this subgroup of patients (160-300 mg rather than 75-100 mg).
Disciplines :
Endocrinology, metabolism & nutrition Cardiovascular & respiratory systems
Author, co-author :
Legrand, Delphine ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Prevention cardiovasculaire par l'aspirine chez le patient diabetique: que nous apprend la medecine factuelle?
Alternative titles :
[fr] Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?
Patrono C, Garcia Rodriguez L, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13.
Barrett-Connor E, Giardina EG, Gitt AK, et al. Women and heart disease: The role of diabetes and hyperglycemia. Arch Intern Med 2004;164:934-42.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
Biondi-Zoccai GG, Abbate A, Liuzzo G, et al. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071-7.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type-2 diabetes. Diabetes Care 2001;24:1476-85.
Colwell JA, Nesto RW. The platelet in diabetes. Focus on prevention of ischemic events. Diabetes Care 2003;26:2181-8.
Nowak SN, Jaber LA. Aspirin dose for prevention of cardiovascular disease in diabetics. Ann Pharmacother 2003;37:116-21.
Krein SL, Vijan S, Pogach LM, et al. Aspirin use and counselling about aspirin among patients with diabetes. Diabetes Care 2002;25:965-70.
Persell SD, Baker DW. Aspirin use among adults with diabetes. Recent trends and emerging sex disparities. Arch Intern Med 2004;164:2492-9.
Wexler DJ, Grant RW, Meigs JB, et al. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005;28:514-20.
American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004;27:S72-3.
Pearson TA, Steven N, Blair SN, et al. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke. Circulation 2002;106:388-91.
Charbonnel B, Bouhanick B, Le Feuvre C et le Groupe de travail. Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue. Arch Mal Cœur Vaiss 2004;97:229-49.
U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med 2002;136:157-60.
ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report 14. JAMA 1992;268:1292-300.
Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
Hansson L, Zanchetti A, Carruthers SG, et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet 2001;357:89-95.
Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 2003;26:3264-72.
Evangelista V, Totani L, Rotondo S, et al. Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin. Thromb Haemost 2005;93:8-16.
Patrono C. Insulin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-3.
Mehta SS, Silver RJ, Aaronson A, et al. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 2006;97:567-70.
Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005;83:148-58.
Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 2005;57(Suppl):42-58.
Abaci A, Yilmaz Y, Caliskan M, et al. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res 2005;116:465-70.
Takahashi S, Ushida M, Komine R, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res, available online 21 June 2006.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-5.
Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
De La Cruz JP, Arrebola MM, Villalobos MA, et al. Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur J Pharmacol 2004;484:19-27.
Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) - its relation to metabolic control. Thromb Res 2004;113:101-13.
Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004;25:166-81.
Hennekens CH, Knatterud GL, Pfeffer MA. Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes. Clinical and research challenges. Diabetes Care 2004;27:2752-4
